Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan, Taiwan, ROC; Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan, ROC.
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, ROC.
Biochem Pharmacol. 2017 Apr 1;129:14-25. doi: 10.1016/j.bcp.2017.01.005. Epub 2017 Jan 16.
Dengue virus (DENV) infection has a considerable health impact in tropical and subtropical countries worldwide. Escalation of infection rates greatly increases morbidity and mortality, most commonly from deaths due to dengue hemorrhagic fever and dengue shock syndrome. Although the development of an effective, long-lasting vaccine has been a major aim for control and prevention of DENV infection, the currently licensed vaccine has limitations and is less than satisfactory. Thus, there remains an important need to identify effective and tolerable medications for treatment of DENV-infected patients both in the early phase, to prevent progression to fatal outcomes, and to minimize deaths after patients develop severe complications. This review will address several specific points, including (1) approaches to identify anti-DENV medications, (2) recent advances in the development of potential compounds targeting DENV infection, (3) experience with clinical trials of regimens for DENV infection, (4) some available medications of potential for clinical trials against DENV infection, (5) reasons for unsuccessful outcomes and challenges of anti-DENV treatments, and (6) directions for developing or selecting better anti-DENV strategies. This review provides useful guidance for clinicians selecting drugs for DENV-infected patients with severe manifestations or potential fatal disease progression, and for basic researchers seeking to develop effective anti-DENV regimens.
登革病毒（DENV）感染在全球热带和亚热带国家造成了相当大的健康影响。感染率的上升大大增加了发病率和死亡率，最常见的是因登革出血热和登革休克综合征导致的死亡。尽管开发有效、持久的疫苗一直是控制和预防 DENV 感染的主要目标，但目前许可的疫苗存在局限性，并不令人满意。因此，仍然需要确定有效和可耐受的药物，用于治疗 DENV 感染患者，无论是在早期阶段，以防止进展为致命结局，还是在患者出现严重并发症后最大限度地减少死亡。这篇综述将涉及几个具体方面，包括 (1) 鉴定抗 DENV 药物的方法，(2) 针对 DENV 感染的潜在化合物开发的最新进展，(3) DENV 感染治疗方案临床试验的经验，(4) 一些可能用于 DENV 感染临床试验的现有药物，(5) 抗 DENV 治疗不成功的原因和挑战，以及 (6) 开发或选择更好的抗 DENV 策略的方向。这篇综述为临床医生选择治疗重症或有潜在致命疾病进展的 DENV 感染患者的药物提供了有用的指导，并为寻求开发有效抗 DENV 方案的基础研究人员提供了指导。
